Healthcare / Healthcare PlansNYSE
$274.19
+2.19 (+0.80%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $9.0B · quality 62.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$72.5B
P/E
2.4x
↓EV/EBITDA
N/A
•ROE
14.3%
↑Gross Margin
N/A
•Debt/Equity
0.75
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2016–2025 · 9 años de histórico normalizado
Revenue CAGR
+23.9%
FCF CAGR
+10.0%
FCF margin
3.1%
FCF / Net income
1.41x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $274.88B · net income $5.96B · FCF $8.39B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | $274.88B | $274.88B | $246.15B | $4852.48B | $179.36B | $174.07B | $160.40B | $153.57B | $48.65B | $41.81B | $39.84B |
| Net Income | $5.96B | $5.96B | $3.43B | $25.82B | $6.70B | $5.42B | $8.49B | $5.12B | $2.65B | $2.23B | $1.84B |
| EBITDA | — | — | $9.48B | $171.22B | $12.56B | $10.86B | $10.96B | $11.73B | $4.86B | $4.51B | $3.70B |
| EPS | 110.90 | 110.90 | 60.60 | 86.95 | 21.41 | 15.75 | 22.96 | 13.44 | 10.54 | 8.77 | 7.19 |
| Gross Margin | — | — | 10.2% | 12.4% | 12.5% | — | — | — | — | — | — |
| Operating Margin | — | — | 3.4% | -1.8% | 4.1% | 4.6% | 5.1% | 5.3% | 8.6% | 9.4% | 7.8% |
| Net Margin | 2.2% | 2.2% | 1.4% | 0.5% | 3.7% | 3.1% | 5.3% | 3.3% | 5.4% | 5.3% | 4.6% |
| Balance Sheet | |||||||||||
| Debt/Equity | 0.75 | 0.75 | 0.78 | 0.67 | 0.70 | — | — | — | — | — | — |
| Current Ratio | 0.82 | 0.82 | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||
| Free Cash Flow | $8.39B | $8.39B | $8.96B | $10.24B | $7.36B | — | — | $8.44B | $3.24B | $3.62B | $3.56B |
| Returns | |||||||||||
| ROE | 14.3% | 14.3% | 8.4% | 55.9% | 15.0% | 11.5% | 16.9% | 11.3% | 6.4% | 16.3% | — |
| Valuation | |||||||||||
| P/E | 2.43 | 2.43 | 4.63 | 3.61 | 14.14 | — | — | — | — | — | — |
| EV/EBITDA | — | — | 44.51 | 2.85 | 9.55 | — | — | — | — | — | — |
| P/B | 8.90 | 8.90 | 9.69 | 10.07 | 2.12 | — | — | — | — | — | — |
| Growth & Yield | |||||||||||
| Revenue Growth | 11.7% | 11.7% | -94.9% | 2605.4% | — | 8.5% | 4.5% | 215.7% | 16.4% | 4.9% | — |
| EPS Growth | 83.0% | 83.0% | -30.3% | 306.1% | — | -31.4% | 70.8% | 27.5% | 20.2% | 22.0% | — |
| Dividend Yield | 2.3% | 2.3% | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-39.7%
EPS terminal req.
$24.33
Spread vs growth
122.7%
5Y implied EPS CAGR
-23.3%
EPS terminal req.
$29.44
Spread vs growth
106.3%
10Y implied EPS CAGR
-8.1%
EPS terminal req.
$47.41
Spread vs growth
91.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.0%
Start / end P/E
5.2x → 2.5x
EPS bridge
60.60 → 110.90
Residual
-43.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.